Hims & Hers Health (NYSE:HIMS) Trading Down 6.3% After Analyst Downgrade

Hims & Hers Health, Inc. (NYSE:HIMS) was down 6.3% on Tuesday after BTIG Research downgraded the stock from a buy rating to a neutral rating. The stock traded as low as $13.74 and last traded at $14.5370. Approximately 17,816,646 shares were traded during trading, a decline of 34% from the average daily volume of 26,829,002 shares. The stock had previously closed at $15.51.

Other equities research analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft set a $31.00 price target on Hims & Hers Health and gave the company a “hold” rating in a research report on Tuesday, February 10th. Leerink Partners upgraded Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Citigroup lowered their price target on shares of Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating for the company in a report on Monday, February 9th. Evercore began coverage on shares of Hims & Hers Health in a research report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price target on the stock. Finally, Bank of America reduced their price objective on shares of Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating on the stock in a research note on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $35.71.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the transaction, the insider owned 169,940 shares in the company, valued at approximately $6,238,497.40. This represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 23,090 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $35.72, for a total value of $824,774.80. Following the transaction, the chief financial officer directly owned 94,333 shares in the company, valued at $3,369,574.76. The trade was a 19.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 82,963 shares of company stock worth $2,944,621 in the last quarter. Company insiders own 17.71% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Q4 earnings beat consensus — HIMS reported EPS above estimates and revenue up ~28% year‑over‑year, showing improving profitability that relieved some investor concerns. Press Release
• Positive Sentiment: Full‑year 2026 revenue outlook raised/confirmed — management set 2026 revenue guidance of roughly $2.7B–$2.9B, which analysts viewed as at or above consensus and supports a growth narrative. Reuters
• Neutral Sentiment: Acquisition expands international footprint — Hims agreed to acquire Eucalyptus for up to $1.15B to accelerate global specialty launches; strategic upside exists but the deal is large and integration/financing risks remain. InsiderMonkey
• Negative Sentiment: Near‑term revenue guidance missed Wall Street — Q1 2026 revenue guidance of $600M–$625M came in below consensus (~$650M), prompting investor concern about near‑term growth momentum. Yahoo Finance
• Negative Sentiment: SEC investigation disclosed over compounding of GLP‑1 products — regulatory and legal scrutiny around its weight‑loss drugs increases execution and litigation risk. MSN
• Negative Sentiment: Analyst downgrade — BTIG cut HIMS from Buy to Neutral, adding selling pressure amid the mixed results and regulatory noise. The Fly
• Negative Sentiment: Investor concerns about aggressive expansion and marketing spend — commentary about international push and recent high‑profile marketing (e.g., Super Bowl) raised profitability worries. MarketWatch

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after acquiring an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health in the first quarter valued at approximately $30,000. D.A. Davidson & CO. bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $788,000. Ethic Inc. purchased a new position in shares of Hims & Hers Health during the second quarter valued at approximately $348,000. Finally, AlphaQuest LLC grew its holdings in Hims & Hers Health by 110.2% during the second quarter. AlphaQuest LLC now owns 7,288 shares of the company’s stock worth $363,000 after buying an additional 3,821 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Price Performance

The firm has a market cap of $3.27 billion, a P/E ratio of 26.57, a P/E/G ratio of 2.92 and a beta of 2.43. The company has a fifty day moving average of $28.21 and a 200-day moving average of $40.02. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same period last year, the business earned $0.11 EPS. The business’s revenue was up 28.4% on a year-over-year basis. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its board has authorized a stock repurchase program on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.